Lung cancer combo trial halted early – too few patients to draw conclusions
NCT ID NCT02257619
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested whether adding itacitinib to standard chemotherapy (docetaxel) could help people with advanced non-small cell lung cancer live longer. The trial was stopped early after enrolling only 9 participants, so we cannot tell if the combination is safe or effective. The main goal was to find the right dose and check for serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
itacitinib and docetaxel
What this could lead to
If it worked, this combination might have offered a new treatment option for advanced lung cancer patients who had already tried one prior chemotherapy.
What could go wrong
The trial was terminated early with only 9 participants, so we have very little data. It is unclear if itacitinib adds any benefit or causes more side effects than docetaxel alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CARCINOMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Hot Springs, Arizona, United States
-
Study site
Los Angeles, California, United States
-
Study site
Washington D.C., District of Columbia, United States
-
Study site
Orlando, Florida, United States
-
Study site
Detroit, Michigan, United States
-
Study site
Pascagoula, Mississippi, United States
-
Study site
Kansas City, Missouri, United States
-
Study site
Omaha, Nebraska, United States
-
Study site
Lebanon, New Hampshire, United States
-
Study site
Goldsboro, North Carolina, United States
-
Study site
Cleveland, Ohio, United States
-
Study site
Gettysburg, Pennsylvania, United States
-
Study site
Hershey, Pennsylvania, United States
-
Study site
Pawtucket, Rhode Island, United States
-
Study site
Spartanburg, South Carolina, United States
-
Study site
Round Rock, Texas, United States